Trial reportOpen heart2026
Effect of a mobile health intervention optimised with artificial intelligence on blood pressure and other cardiovascular risk factors in adults with high blood pressure: rationale and design of My Intelligent Cardiac Assistant (MICArdiac) randomised controlled trial.
Trial report in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionControl of blood pressure (BP) continues to be a challenge globally. Clinical trials have shown home BP monitoring and text-message interventions to lower BP. Integrating these to personalise supportive messaging in response to changing BP and activity through leveraging artificial intelligence (AI) could improve BP control. The aim of this trial is to examine the impact on BP, compared with a text-message only programme, of the My Intelligent Cardiac Assistant (MICArdiac) programme. MICArdiac is a 6-month programme comprising tracking of BP, physical activity and heart rate informing a content stream of AI-driven personalised messages to encourage BP self-management, as-necessary medical review to up-titrate medicines and cardiovascular preventative behavioural change. METHODS AND ANALYSIS: MICArdiac is a prospective randomised open-blinded endpoint randomised controlled trial with 1:1 (intervention:control) allocation and active control. Individuals aged 35 years old or above with high BP are randomised to the MICArdiac programme or to a text-message cardiovascular education programme. Recruitment started in primary care and hospital clinics in Western Sydney and moved to decentralised direct-to-community recruitment in the Australian Capital Territory, New South Wales and Victoria. Randomisation and allocation concealment occur via a secure web-based system. The primary outcome is mean daytime systolic BP measured by 24-hour Ambulatory Blood Pressure Monitoring at 6 months. Primary analysis will follow intention-to-treat principles; data analysts will be blinded. Process evaluation will be conducted. ETHICS AND DISSEMINATION: Ethics approval was obtained from Western Sydney Local Health District Human Ethics Research Committee (2021/ETH11379). TRIAL REGISTRATION NUMBER: ACTRN12622000091707.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.